Thallion Pharmaceuticals Inc. (TSX:TLN) announced it has conventional leave from the
Therapeutic stock Directorate of Health Canada to initiate a Phase II clinical trial evaluating
TLN-232 as a regimen for metastatic melanoma in next that have failed ...
(more)